Cargando…

Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity

BACKGROUND: Multiple vaccines have been approved since August 2021 to prevent infection with SARS-CoV-2; however, 20–40% of immunocompromised people fail to develop SARS-CoV-2 spike antibodies after COVID-19 vaccination and remain at high risk of infection and more severe illness than non-immunocomp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez-Bocco, Isabel H., Beluch, Katherine, Cho, Alyssa, Lahoud, Chloe, Reyes, Fabiola A., Moshovitis, Dimitrios G., Unger-Mochrie, Gillian M., Wang, Wei, Hammond, Sarah P., Manne-Goehler, Jennifer, Koo, Sophia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10273764/ https://www.ncbi.nlm.nih.gov/pubmed/37328890 http://dx.doi.org/10.1186/s40814-023-01325-y

Ejemplares similares

2715. Toxicities and clinical consequences of valganciclovir prophylaxis in solid organ transplant recipients
por: Lahoud, Chloe, et al.
Publicado: (2023)

1399. Clarithromycin–Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2021)

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma
por: Little, Jessica S., et al.
Publicado: (2022)

SARS-CoV-2 Pre-Exposure Prophylaxis with Sotrovimab and Tixagevimab/Cilgavimab in Immunocompromised Patients—A Single-Center Experience
por: Totschnig, David, et al.
Publicado: (2022)

Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2021)

Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
por: Birk, Navina K, et al.
Publicado: (2022)

Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022)

Sotrovimab for COVID-19
Publicado: (2021)

Sotrovimab: First Approval
por: Heo, Young-A
Publicado: (2022)

Rapid Selection of Sotrovimab Escape Variants in Severe Acute Respiratory Syndrome Coronavirus 2 Omicron-Infected Immunocompromised Patients
por: Gliga, Smaranda, et al.
Publicado: (2022)

Antifungal Prophylaxis in Immunocompromised Patients
por: Vazquez, Lourdes
Publicado: (2016)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

Sotrovimab Resistance and Viral Persistence After Treatment of Immunocompromised Patients Infected With the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant
por: Huygens, Sammy, et al.
Publicado: (2022)

497. Safety and tolerability of 2000mg intravenous sotrovimab dose in immunocompromised participants uninfected with SARS-CoV-2 in the PROTECT-V trial
por: Dosanjh, Davinder, et al.
Publicado: (2023)

186. Evaluating Clinical Outcomes for Treatment of Staphylococcal Bloodstream Infection in Patients with Febrile Neutropenia
por: Aleissa, Muneerah M, et al.
Publicado: (2021)

1231. VIR-2482: A potent and broadly neutralizing antibody for the prophylaxis of influenza A illness
por: Pizzuto, Matteo Samuele, et al.
Publicado: (2020)

Monitoring of Sotrovimab-Levels as Pre-Exposure Prophylaxis in Kidney Transplant Recipients Not Responding to SARS-CoV-2 Vaccines
por: Aschauer, Constantin, et al.
Publicado: (2023)

Nocardiosis in Immunocompromised Patients on Alternative Pneumocystis Prophylaxis
por: Puing, Alfredo G., et al.
Publicado: (2021)

Beatus vir Totus tuus ; Old Polish music /
por: Górecki, Henryk Miko{lstrok}aj, 1933-
Publicado: (1993)

Humoral and cellular response to the COVID-19 vaccine in immunocompromised children
por: Morgans, Heather A., et al.
Publicado: (2022)

Sotrovimab: Emergence of acquired resistance: 4 case reports
Publicado: (2022)

Clinical practice update of antifungal prophylaxis in immunocompromised children
por: Ramos, José Tomás, et al.
Publicado: (2019)

Post-exposure prophylaxis to prevent varicella in immunocompromised children
por: Yamaguchi, Makoto, et al.
Publicado: (2022)

Evaluation of the Chagas VirClia(®) and Chagas TESA VirClia(®) for the Diagnosis of Trypanosoma cruzi Infection
por: García-Bermejo, Isabel, et al.
Publicado: (2022)

Resistance mutations in SARS-CoV-2 omicron variant in patients treated with sotrovimab
por: Vellas, Camille, et al.
Publicado: (2022)

Interaction via the N terminus of the type IV secretion system (T4SS) protein VirB6 with VirB10 is required for VirB2 and VirB5 incorporation into T-pili and for T4SS function
por: Mary, Charline, et al.
Publicado: (2018)

VirF-Independent Regulation of Shigella virB Transcription is Mediated by the Small RNA RyhB
por: Broach, William H., et al.
Publicado: (2012)

Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection
por: Gupta, Isha, et al.
Publicado: (2022)

Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series
por: Cicchitto, Gaetano, et al.
Publicado: (2022)

Immunogenic Response of Brucella canis virB10 and virB11 Mutants in a Murine Model
por: Palomares-Resendiz, E., et al.
Publicado: (2012)

Humoral and cellular immune response to Plasmodium vivax VIR recombinant and synthetic antigens in individuals naturally exposed to P. vivax in the Republic of Korea
por: Lee, Sanghyun, et al.
Publicado: (2021)

Structure of a VirD4 coupling protein bound to a VirB type IV secretion machinery
por: Redzej, Adam, et al.
Publicado: (2017)

The Impact of Bartonella VirB/VirD4 Type IV Secretion System Effectors on Eukaryotic Host Cells
por: Fromm, Katja, et al.
Publicado: (2021)

733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.
por: Gonzalez-Bocco, Isabel H, et al.
Publicado: (2022)

Travel advice for the immunocompromised traveler: prophylaxis, vaccination, and other preventive measures
por: Patel, Rupa R, et al.
Publicado: (2015)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

512. Interim Results of a Prospective Cohort Study to Monitor the Emergence of Resistance in Immunocompromised Non-Hospitalized Patients With COVID-19 Who Were Treated with Sotrovimab in Great Britain: LUNAR Study 
por: Breuer, Judith, et al.
Publicado: (2023)

DBatVir: the database of bat-associated viruses
por: Chen, Lihong, et al.
Publicado: (2014)

The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study
por: Aleissa, Muneerah M, et al.
Publicado: (2022)

The VirF(21):VirF(30) protein ratio is affected by temperature and impacts Shigella flexneri host cell invasion
por: Skovajsová, Eva, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_51ju4820n4b0ndmcfalnl98bmf